Oxford BioMedica PLC (OXBDF)

[marcusl2]

Analyst John Newman of Canaccord Genuity;

"We view the Novartis briefing documents as suggestive of FDA support for approval, and beneficial to all CART players. Importantly, we will listen carefully to any details on manufacturing, which may benefit KITE. We believe safety for the CART class, specifically CRS, will be carefully managed, and will not prevent a positive panel vote and FDA approval."

Canaccord analyst John Newman reiterated his "Buy" rating and $115 price target on Kite Pharma Tuesday, saying that the briefing documents from Novartis thus far are positive.